1
|
Fisher AD, Fisher G. Evaluating performance of custom GPT in anesthesia practice. J Clin Anesth 2024; 93:111371. [PMID: 38154443 DOI: 10.1016/j.jclinane.2023.111371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Accepted: 12/21/2023] [Indexed: 12/30/2023]
Affiliation(s)
- Andrew D Fisher
- Medical University of South Carolina, Department of Anesthesia and Perioperative Medicine, 167 Ashley Avenue, Suite 301, Charleston, SC 29464, United States of America.
| | - Gabrielle Fisher
- Medical University of South Carolina, Department of Anesthesia and Perioperative Medicine, 167 Ashley Avenue, Suite 301, Charleston, SC 29464, United States of America
| |
Collapse
|
2
|
Fisher AD, Fisher G. Danger, Danger, Gaston Labat! Does zero-shot artificial intelligence correlate with anticoagulation guidelines recommendations for neuraxial anesthesia? Reg Anesth Pain Med 2024:rapm-2024-105405. [PMID: 38418408 DOI: 10.1136/rapm-2024-105405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 02/19/2024] [Indexed: 03/01/2024]
Affiliation(s)
- Andrew D Fisher
- Department of Anesthesia & Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Gabrielle Fisher
- Department of Anesthesia & Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| |
Collapse
|
3
|
Valente IE, Fisher G, Wolf BJ, Tanious MK. Code Status Discussions in Pediatric Patients With Heart Disease During Terminal Admissions. Pediatrics 2023; 152:e2023063221. [PMID: 37936505 DOI: 10.1542/peds.2023-063221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/25/2023] [Indexed: 11/09/2023] Open
Affiliation(s)
- Isabella E Valente
- Department of Anesthesiology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina
| | - Gabrielle Fisher
- Department of Anesthesiology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina
| | - Bethany J Wolf
- Department of Anesthesia and Perioperative Medicine
- Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina
| | | |
Collapse
|
4
|
Gianoukakis A, Arnold S, Kahn S, Taylor M, Garralda E, Krebs M, Arkenau HT, Clark L, Fisher G, Subbiah V. 82TiP A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00336-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
5
|
Fisher AD, Fisher G. Anesthesiologists and Voter Advocacy: A Novel Avenue for Civic Outreach. Anesth Analg 2023; 136:616-620. [PMID: 36806236 DOI: 10.1213/ane.0000000000006144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- Andrew D Fisher
- From the Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina
| | | |
Collapse
|
6
|
Bearne L, Volkmer B, Dhouri A, Farran D, Fisher G, Galea Holmes M, Modarai B, Patel S, Peacock J, Sackley C, Weinman J, Bieles J. A physiotherapist-led, home-based walking intervention for peripheral arterial disease: MOtivating Structured walking Activity for Intermittent Claudication (MOSAIC) randomised controlled trial. Physiotherapy 2022. [DOI: 10.1016/j.physio.2021.12.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Bieles J, Volkmer B, Holmes MG, Duvnjak S, Fisher G, Keane R, Modarai B, Peacock J, Weinman J, Sackley C, Bearne L. The impact of the motivating structured walking activity for intermittent claudication training for physiotherapists on therapeutic empathy and motivational interviewing. Physiotherapy 2021. [DOI: 10.1016/j.physio.2021.10.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Chen D, Barsoumian H, Fisher G, Yang L, Vellano C, Marszalek J, Davies M, Cortez M, Welsh J. Combination Treatment With Radiotherapy And A Novel Oxidative Phosphorylation Inhibitor Overcomes PD-1 Resistance And Enhances Antitumor Immunity. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1687] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Forrester S, Fisher G, Chieng CY, Rogers SN. Oral and maxillofacial dental care professionals in critical care during the COVID-19 pandemic. Br J Oral Maxillofac Surg 2020; 59:117-120. [PMID: 33218695 PMCID: PMC7446613 DOI: 10.1016/j.bjoms.2020.08.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Accepted: 08/16/2020] [Indexed: 11/04/2022]
Abstract
At the peak of the COVID-19 pandemic there was a ‘call to arms’ across the oral and maxillofacial staff. This article reports on the extended role of the department's dental care professionals (DCPs) and the tremendous opportunity and value that temporary redeployment presented.
Collapse
Affiliation(s)
- S Forrester
- Dental Nurse, Oral & Maxillofacial Surgery and Orthodontics Department, Arrowe Park Hospital, Wirral CH49 5PE, UK.
| | - G Fisher
- Dental Hygienist, DipDHE, Oral & Maxillofacial Surgery and Orthodontics Department, Arrowe Park Hospital, Wirral CH49 5PE, UK.
| | - C Y Chieng
- Dental Core Trainee, BDS, Oral & Maxillofacial Surgery Department, Arrowe Park Hospital, Wirral CH49 5PE, UK.
| | - S N Rogers
- Consultant in Oral & Maxillofacial Surgery, FRCS (OMFS) MD, Faculty of Health and Social Care, Edge Hill University, Ormskirk, L39 4QP and Liverpool Head and Neck Cancer Centre, Liverpool University Hospital Aintree, Liverpool L9 7AL, UK.
| |
Collapse
|
10
|
Fisher G, Smith RD, Saridogan E, Vashisht A, Allen S, Arumuham V, Cutner A. Case selection for urological input in planned laparoscopic rectovaginal endometriosis surgery. Facts Views Vis Obgyn 2019; 11:111-117. [PMID: 31824632 PMCID: PMC6897523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Surgery for deep endometriosis often requires input from urological surgeons. This study aims to determine pre-operative and intra-operative factors that influence the need for urological input in laparoscopic resection of rectovaginal endometriosis and to assess the usefulness of a scoring system to predict this. METHODS We conducted a retrospective cohort study of 230 patients undergoing laparoscopic excision of deep endometriosis, at a tertiary referral centre for endometriosis in London UK, 2011 to 2015. Data from pre-operative assessment, surgery and post-operative follow up were analysed and patients were categorised according to their pre-operative and intra-operative risk factors. The primary outcome measure was the requirement of intra-operative input by urological surgeons. RESULTS The median age was 35 years. In addition to the excision of endometriosis, 19.6% patients (45 patients) underwent hysterectomy, 14.8% (34 patients) required JJ stent placement, 6.1% (14 patients) had bowel resections and 2.6% (6 patients) required an ileostomy. 93.9% (216 patients) were considered normal-risk pre-operatively, of whom 89.4% (193/216) did not require any intra-operative urological input. 10.6% of this normal-risk group (23/216) required JJ stents, of whom 69.6% (16/23) also required a hysterectomy or bowel resection. Post operative complications occurred in 0.9% (2/216) of normal-risk patients, with none having required intra-operative urological reconstruction.Six percent (14 patients) were deemed to be increased-risk pre-operatively, of whom 78.6% (11/14) required JJ stent insertion. Thirty-six percent of increased-risk patients (5/14) had pre-operative renal dysfunction demonstrated on MAG3/DMSA and 80.0% of these (4/5) required intra-operative ureteric reconstruction. CONCLUSIONS Patients considered normal-risk pre-operatively, planned for excision, without hysterectomy or bowel resection, can be safely managed without specific urology input. Patients with risk-features are highly likely to require urological input, particularly for JJ stent insertion. Patients with pre-operative renal dysfunction, demonstrated on MAG3/DMSA, have a high chance of requiring intra-operative ureteric reconstruction and are best managed with pre-planned reconstructive urologist input.
Collapse
Affiliation(s)
- G Fisher
- Endometriosis Unit, Department of Women’s Health, University College Hospital London, 235 Euston Rd, London, NW1 2BU, United Kingdom
| | - RD Smith
- Department of Endoluminal Endourology, Institute of Urology, University College Hospital
London, 16-18 Westmoreland Street, London, W1G 8PH, United Kingdom
| | - E Saridogan
- Endometriosis Unit, Department of Women’s Health, University College Hospital London, 235 Euston Rd, London, NW1 2BU, United Kingdom
| | - A Vashisht
- Endometriosis Unit, Department of Women’s Health, University College Hospital London, 235 Euston Rd, London, NW1 2BU, United Kingdom
| | - S Allen
- Department of Endoluminal Endourology, Institute of Urology, University College Hospital
London, 16-18 Westmoreland Street, London, W1G 8PH, United Kingdom
| | - V Arumuham
- Department of Endoluminal Endourology, Institute of Urology, University College Hospital
London, 16-18 Westmoreland Street, London, W1G 8PH, United Kingdom
| | - A Cutner
- Endometriosis Unit, Department of Women’s Health, University College Hospital London, 235 Euston Rd, London, NW1 2BU, United Kingdom
| |
Collapse
|
11
|
Neal CA, Brantley SR, Antolik L, Babb JL, Burgess M, Calles K, Cappos M, Chang JC, Conway S, Desmither L, Dotray P, Elias T, Fukunaga P, Fuke S, Johanson IA, Kamibayashi K, Kauahikaua J, Lee RL, Pekalib S, Miklius A, Million W, Moniz CJ, Nadeau PA, Okubo P, Parcheta C, Patrick MR, Shiro B, Swanson DA, Tollett W, Trusdell F, Younger EF, Zoeller MH, Montgomery-Brown EK, Anderson KR, Poland MP, Ball JL, Bard J, Coombs M, Dietterich HR, Kern C, Thelen WA, Cervelli PF, Orr T, Houghton BF, Gansecki C, Hazlett R, Lundgren P, Diefenbach AK, Lerner AH, Waite G, Kelly P, Clor L, Werner C, Mulliken K, Fisher G, Damby D. The 2018 rift eruption and summit collapse of Kīlauea Volcano. Science 2018; 363:367-374. [PMID: 30538164 DOI: 10.1126/science.aav7046] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Accepted: 12/03/2018] [Indexed: 11/02/2022]
Abstract
In 2018, Kīlauea Volcano experienced its largest lower East Rift Zone (LERZ) eruption and caldera collapse in at least 200 years. After collapse of the Pu'u 'Ō'ō vent on 30 April, magma propagated downrift. Eruptive fissures opened in the LERZ on 3 May, eventually extending ~6.8 kilometers. A 4 May earthquake [moment magnitude (M w) 6.9] produced ~5 meters of fault slip. Lava erupted at rates exceeding 100 cubic meters per second, eventually covering 35.5 square kilometers. The summit magma system partially drained, producing minor explosions and near-daily collapses releasing energy equivalent to M w 4.7 to 5.4 earthquakes. Activity declined rapidly on 4 August. Summit collapse and lava flow volume estimates are roughly equivalent-about 0.8 cubic kilometers. Careful historical observation and monitoring of Kīlauea enabled successful forecasting of hazardous events.
Collapse
Affiliation(s)
- C A Neal
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA.
| | - S R Brantley
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - L Antolik
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - J L Babb
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - M Burgess
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - K Calles
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - M Cappos
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - J C Chang
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - S Conway
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - L Desmither
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - P Dotray
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - T Elias
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - P Fukunaga
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - S Fuke
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - I A Johanson
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - K Kamibayashi
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - J Kauahikaua
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - R L Lee
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - S Pekalib
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - A Miklius
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - W Million
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - C J Moniz
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - P A Nadeau
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - P Okubo
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - C Parcheta
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - M R Patrick
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - B Shiro
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - D A Swanson
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - W Tollett
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - F Trusdell
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - E F Younger
- U.S. Geological Survey, Hawaiian Volcano Observatory, 51 Crater Rim Dr., Hawai'i National Park, Hawaii, HI 96718, USA
| | - M H Zoeller
- Center for the Study of Active Volcanoes, University of Hawai'i at Hilo, 200 W. Kāwili St., Hilo, HI 96720, USA
| | - E K Montgomery-Brown
- U.S. Geological Survey, California Volcano Observatory, 345 Middlefield Rd., Menlo Park, CA 94025, USA.
| | - K R Anderson
- U.S. Geological Survey, California Volcano Observatory, 345 Middlefield Rd., Menlo Park, CA 94025, USA
| | - M P Poland
- U.S. Geological Survey, Yellowstone Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - J L Ball
- U.S. Geological Survey, California Volcano Observatory, 345 Middlefield Rd., Menlo Park, CA 94025, USA
| | - J Bard
- U.S. Geological Survey, Cascades Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - M Coombs
- U.S. Geological Survey, Alaska Volcano Observatory, 4230 University Dr., Anchorage, AK 99508, USA
| | - H R Dietterich
- U.S. Geological Survey, Alaska Volcano Observatory, 4230 University Dr., Anchorage, AK 99508, USA
| | - C Kern
- U.S. Geological Survey, Cascades Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - W A Thelen
- U.S. Geological Survey, Cascades Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - P F Cervelli
- U.S. Geological Survey, Alaska Volcano Observatory, 4230 University Dr., Anchorage, AK 99508, USA
| | - T Orr
- U.S. Geological Survey, Alaska Volcano Observatory, 4230 University Dr., Anchorage, AK 99508, USA
| | - B F Houghton
- Department of Earth Sciences, University of Hawai'i at Manoa, 1680 East-West Rd., Honolulu, HI 96822, USA
| | - C Gansecki
- Geology Department, University of Hawai'i at Hilo, 200 W. Kāwili St., Hilo, HI 96720, USA
| | - R Hazlett
- Geology Department, University of Hawai'i at Hilo, 200 W. Kāwili St., Hilo, HI 96720, USA
| | - P Lundgren
- Jet Propulsion Laboratory, California Institute of Technology, 4800 Oak Grove Dr., Pasadena, CA 91109, USA
| | - A K Diefenbach
- U.S. Geological Survey, Cascades Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - A H Lerner
- Department of Earth Sciences, University of Oregon, 100 Cascades Hall, Eugene, OR 97403, USA
| | - G Waite
- Department of Geological and Mining Engineering and Sciences, Michigan Technological University, 630 Dow Environmental Sciences, 1400 Townsend Dr., Houghton, MI 49931, USA
| | - P Kelly
- U.S. Geological Survey, Cascades Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - L Clor
- U.S. Geological Survey, Cascades Volcano Observatory, 1300 SE Cardinal Ct., Suite 100, Vancouver, WA 98683-9589, USA
| | - C Werner
- U.S. Geological Survey Contractor, 392 Tukapa St., RD1, New Plymouth 4371, New Zealand
| | - K Mulliken
- State of Alaska Division of Geological and Geophysical Surveys, Alaska Volcano Observatory, 3354 College Rd., Fairbanks, AK 99709, USA
| | - G Fisher
- U.S. Geological Survey, National Civil Applications Center, 12201 Sunrise Valley Dr., MS-562, Reston, VA 20192, USA
| | - D Damby
- U.S. Geological Survey, California Volcano Observatory, 345 Middlefield Rd., Menlo Park, CA 94025, USA
| |
Collapse
|
12
|
Affiliation(s)
- G Fisher
- Colorado State University, Fort Collins, Colorado, United States
| | - M F Steger
- Department of Psychology, Colorado State University, Fort Collins, CO
| | - A Sonnega
- Survey Research Center, University of Michigan, Ann Arbor, MI
| | - L H Ryan
- Survey Research Center, University of Michigan, Ann Arbor, MI
| |
Collapse
|
13
|
Graham K, Fisher G, Davalos D. VOLUNTEERISM IN OLDER ADULTHOOD: UNDERSTANDING THE FACTORS ASSOCIATED WITH WELL-BEING. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Fisher G, Guerra W, Day C, Montagut C. Optimizing the use of EGFR antibodies across the continuum of care in mCRC: Effect of online education on clinician knowledge, competence and confidence. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Fisher G, Guerra W, Day C, Ducreux M. Treatment based on tumor sidedness in mCRC: Effect of online education on clinician knowledge, competence and confidence. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Bekaii-Saab T, Marcello K, Fisher G, Kopetz S, Strickler J, Venook A, Obholz K. Variability of current global practice patterns in the management of metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Ahmad AS, Parameshwaran V, Beltran L, Fisher G, North BV, Greenberg D, Soosay G, Møller H, Scardino P, Cuzick J, Berney DM. Should reporting of peri-neural invasion and extra prostatic extension be mandatory in prostate cancer biopsies? correlation with outcome in biopsy cases treated conservatively. Oncotarget 2018; 9:20555-20562. [PMID: 29755671 PMCID: PMC5945501 DOI: 10.18632/oncotarget.24994] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 03/15/2018] [Indexed: 11/25/2022] Open
Abstract
The identification of perineural invasion (PNI) and extraprostatic extension (ECE) in prostate cancer (PC) biopsies is time consuming and can be difficult. Although this is required information in many datasets, there is little evidence on their effect on outcome in patients treated conservatively. Cases of PC were identified from three cancer registries in the UK from men with clinically localized prostate cancer diagnosed by needle biopsy from 1990-2003. The endpoint was prostate cancer death (DOD). Patients treated radically within 6 months, those with objective evidence of metastases or who had prior hormone therapy were excluded. Follow-up was through cancer registries up until 2012. Deaths were divided into those from PC and those from other causes, according to WHO criteria. 988 biopsy cases (6522 biopsy cores) were centrally reviewed by three uropathologists and assigned a Gleason score and Grade Group (GG). The presence of both PNI and ECE was recorded. Of 988 patients, PNI was present in 288 (DOD = 75) and ECE in 23 (DOD = 5). On univariable analysis PNI was highly significantly associated with DOD (hazard ratio [HR] 2.28, 95% CI: 1.68, 3.1, log-rank test p-value = 4.8 × 10-8), but ECE was not (log-rank test p-value = 0.334). On multivariable analysis with GG, serum PSA (per 10%), clinical stage and extent of disease (per 10%), PNI lost significance (HR 1.16, 95% CI: 0.83, 1.63, likelihood ratio test p-value = 0.371). The utility of routinely examining prostate biopsies for ECE and PNI is doubtful as it is not independently associated with higher grade, stage or prognosis.
Collapse
Affiliation(s)
- Amar S. Ahmad
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Vishnu Parameshwaran
- Department of Molecular Oncology, Barts Cancer Institute Queen Mary University of London, London, UK
| | - Luis Beltran
- Department of Molecular Oncology, Barts Cancer Institute Queen Mary University of London, London, UK
| | - Gabrielle Fisher
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Bernard V. North
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - David Greenberg
- National Cancer Registration Service (Eastern Office), Public Health England, Cambridge, UK
| | | | - Henrik Møller
- Cancer Epidemiology and Population Health, King's College London, London, UK
| | - Peter Scardino
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Jack Cuzick
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Daniel M. Berney
- Department of Molecular Oncology, Barts Cancer Institute Queen Mary University of London, London, UK
| | - on behalf of the Transatlantic Prostate Group
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
- Department of Molecular Oncology, Barts Cancer Institute Queen Mary University of London, London, UK
- National Cancer Registration Service (Eastern Office), Public Health England, Cambridge, UK
- Department of Pathology, Queen’s Hospital, Romford, Essex, UK
- Cancer Epidemiology and Population Health, King's College London, London, UK
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
18
|
Fisher G, Middleton D, Day C, Harbeck N. Application of CDK4/6 inhibitors in advanced breast cancer: Effect of online education on clinician knowledge, competence and confidence. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30531-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
19
|
Fisher G, Middleton D, Day C, Andre F. Predictive biomarkers for CDK4/6 inhibitors: Effect of online education on clinician knowledge. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30534-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Fisher G, Middleton D, Day C, Di Leo A. Management of HR-positive, HER2-negative advanced breast cancer with CDK4/6 inhibitors: Effect of online education on clinician knowledge, competence and confidence. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30533-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Stankiewicz E, Mao X, Mangham DC, Xu L, Yeste-Velasco M, Fisher G, North B, Chaplin T, Young B, Wang Y, Kaur Bansal J, Kudahetti S, Spencer L, Foster CS, Møller H, Scardino P, Oliver RT, Shamash J, Cuzick J, Cooper CS, Berney DM, Lu YJ. Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer. Sci Rep 2017; 7:5124. [PMID: 28698647 PMCID: PMC5505985 DOI: 10.1038/s41598-017-05209-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Accepted: 05/24/2017] [Indexed: 01/26/2023] Open
Abstract
Prostate cancer is the most common cancer among western men, with a significant mortality and morbidity reported for advanced metastatic disease. Current understanding of metastatic disease is limited due to difficulty of sampling as prostate cancer mainly metastasizes to bone. By analysing prostate cancer bone metastases using high density microarrays, we found a common genomic copy number loss at 6q16.1-16.2, containing the FBXL4 gene, which was confirmed in larger series of bone metastases by fluorescence in situ hybridisation (FISH). Loss of FBXL4 was also detected in primary tumours and it was highly associated with prognostic factors including high Gleason score, clinical stage, prostate-specific antigen (PSA) and extent of disease, as well as poor patient survival, suggesting that FBXL4 loss contributes to prostate cancer progression. We also demonstrated that FBXL4 deletion is detectable in circulating tumour cells (CTCs), making it a potential prognostic biomarker by 'liquid biopsy'. In vitro analysis showed that FBXL4 plays a role in regulating the migration and invasion of prostate cancer cells. FBXL4 potentially controls cancer metastasis through regulation of ERLEC1 levels. Therefore, FBXL4 could be a potential novel prostate cancer suppressor gene, which may prevent cancer progression and metastasis through controlling cell invasion.
Collapse
Affiliation(s)
- Elzbieta Stankiewicz
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Xueying Mao
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - D Chas Mangham
- The Robert Jones and Agnes Hunt Orthopaedic Hospital, Department of Pathology, Oswestry, Shropshire, SY10 7AG, UK
| | - Lei Xu
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Marc Yeste-Velasco
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Gabrielle Fisher
- Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, EC1 6BQ, UK
| | - Bernard North
- Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, EC1 6BQ, UK
| | - Tracy Chaplin
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Bryan Young
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Yuqin Wang
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Jasmin Kaur Bansal
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Sakunthala Kudahetti
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Lucy Spencer
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Christopher S Foster
- Division of Cellular and Molecular Pathology, University of Liverpool, Liverpool, L69 3BX, UK
- HCA Pathology Laboratories, Shropshire House, Capper Street, London, WC1E6JA, UK
| | - Henrik Møller
- King's College London, Cancer Epidemiology and Population Health, London, SE1 9RT, UK
| | - Peter Scardino
- Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - R Tim Oliver
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Jonathan Shamash
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Jack Cuzick
- Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, EC1 6BQ, UK
| | - Colin S Cooper
- School of Medicine, University of East Anglia, Norwich, NR4 7TJ, UK
| | - Daniel M Berney
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Yong-Jie Lu
- Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
| |
Collapse
|
22
|
Hochfellner D, Gutierrez I, Fisher G. INDIVIDUAL, EMPLOYER, AND JOB-RELATED INFLUENCES ON LATE WORK CAREERS OUTCOMES AND WORK ABILITY. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Stankiewicz E, Mao X, Mangham DC, Xu L, Fisher G, North B, Moller H, Scardino P, Cuzick J, Berney D, Lu YJ. Abstract 1614: Identification of FBXL4 as a bone metastasis-associated gene in prostate cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-1614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate cancer (PCa) is the most common cancer among men in Western developed countries. While the majority of PCa diagnosed by PSA screening are indolent, advanced and metastatic disease has a significant mortality and morbidity. Bone metastases are extremely common in PCa and identification of bone metastasis associated genes may provide insights into PCa progression and assist in finding new drug targets. However, the genetic study of bone metastases is very limited due to the difficulty of sampling. By analyzing PCa bone metastases using high density microarrays, we found a common genomic copy number loss at 6q16.1-16.2, containing the FBXL4 gene, which was confirmed in a separate and larger series of bone metastatic samples by fluorescence in situ hybridization (FISH). Loss of FBXL4 was also detected in primary PCa, although at a significantly lower frequency than in bone metastases, and it was highly associated with prognostic factors including high Gleason score, clinical stage, PSA and extent of disease, as well as poor patient survival in conservatively-managed localized PCa, suggesting that loss of FBXL4 contributes to PCa progression. We also demonstrated that FBXL4 deletion is detectable in circulating tumor cells, making it a potential disease prognostic or progression monitoring biomarker by ‘liquid biopsy’. Consistent with loss of FBXL4 being associated with aggressive tumors, we demonstrated in vitro that FBXL4 plays a role in regulating the migration and invasion of PCa cells. Therefore, FBXL4 is a potential novel PCa suppressor gene, which may prevent cancer progression and bone metastasis through controlling cell invasion.
Citation Format: Elzbieta Stankiewicz, Xueying Mao, D Chas Mangham, Lei Xu, Gabrielle Fisher, Bernard North, Henrik Moller, Peter Scardino, Jack Cuzick, Dan Berney, Yong-Jie Lu. Identification of FBXL4 as a bone metastasis-associated gene in prostate cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1614.
Collapse
Affiliation(s)
- Elzbieta Stankiewicz
- 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Xueying Mao
- 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - D Chas Mangham
- 2The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, United Kingdom
| | - Lei Xu
- 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Gabrielle Fisher
- 3Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London, United Kingdom
| | - Bernard North
- 3Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London, United Kingdom
| | - Henrik Moller
- 4King's College London, Cancer Epidemiology and Population Health, London, United Kingdom
| | - Peter Scardino
- 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Jack Cuzick
- 3Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, London, United Kingdom
| | - Dan Berney
- 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Yong-Jie Lu
- 1Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| |
Collapse
|
24
|
Fader A, Diaz L, Armstrong D, Tanner E, Uram J, Eyring A, Wang H, Fisher G, Greten T, Le D. Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer. Gynecol Oncol 2016. [DOI: 10.1016/j.ygyno.2016.04.532] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
25
|
Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P, Cuzick J. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. Br J Cancer 2016; 114:1078-83. [PMID: 27100731 PMCID: PMC4865975 DOI: 10.1038/bjc.2016.86] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 03/10/2016] [Accepted: 03/10/2016] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Gleason scoring (GS) has major deficiencies and a novel system of five grade groups (GS⩽6; 3+4; 4+3; 8; ⩾9) has been recently agreed and included in the WHO 2016 classification. Although verified in radical prostatectomies using PSA relapse for outcome, it has not been validated using prostate cancer death as an outcome in biopsy series. There is debate whether an 'overall' or 'worst' GS in biopsies series should be used. METHODS Nine hundred and eighty-eight prostate cancer biopsy cases were identified between 1990 and 2003, and treated conservatively. Diagnosis and grade was assigned to each core as well as an overall grade. Follow-up for prostate cancer death was until 31 December 2012. A log-rank test assessed univariable differences between the five grade groups based on overall and worst grade seen, and using univariable and multivariable Cox proportional hazards. Regression was used to quantify differences in outcome. RESULTS Using both 'worst' and 'overall' GS yielded highly significant results on univariate and multivariate analysis with overall GS slightly but insignificantly outperforming worst GS. There was a strong correlation with the five grade groups and prostate cancer death. CONCLUSIONS This is the largest conservatively treated prostate cancer cohort with long-term follow-up and contemporary assessment of grade. It validates the formation of five grade groups and suggests that the 'worst' grade is a valid prognostic measure.
Collapse
Affiliation(s)
- Daniel M Berney
- Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, EC1A 7BE London, UK
| | - Luis Beltran
- Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, EC1A 7BE London, UK
| | - Gabrielle Fisher
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, EC1A 7BE London, UK
| | - Bernard V North
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, EC1A 7BE London, UK
| | - David Greenberg
- National Cancer Registration Service (Eastern Office), Public Health England, CB22 3AD Cambridge, UK
| | - Henrik Møller
- Cancer Epidemiology and Population Health, King's College London, SE1 9RT London, UK
| | - Geraldine Soosay
- Department of Pathology, Queen's Hospital, Romford, RM7 0AG Essex, UK
| | - Peter Scardino
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, 10065 NY, USA
| | - Jack Cuzick
- UK Center for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, EC1A 7BE London, UK
| |
Collapse
|
26
|
Wang F, Calderone K, Smith N, Do T, Kang S, Voorhees J, Fisher G. 268 Enhanced dermal mechanical support rapidly stimulates fibroblasts and stable accumulation of collagen bundles in photoaged human skin. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Rittié L, Farr E, Orringer J, Voorhees J, Fisher G. 296 Reduced sweat gland contribution and cell cohesion delay wound closure in elderly skin. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Wang P, Sun M, Xu Y, Xu Y, Voorhees J, Fisher G, Li Y. 267 Once weekly topical all-trans retinol restores type I collagen synthesis in photoaged forearm skin within 4 weeks: A protocol for evaluating anti-aging topical agents. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer M, Scardino P. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 2015; 113:382-9. [PMID: 26103570 PMCID: PMC4522632 DOI: 10.1038/bjc.2015.223] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Revised: 05/12/2015] [Accepted: 05/25/2015] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND The natural history of prostate cancer is highly variable and difficult to predict accurately. Better markers are needed to guide management and avoid unnecessary treatment. In this study, we validate the prognostic value of a cell cycle progression score (CCP score) independently and in a prespecified linear combination with standard clinical variables, that is, a clinical-cell-cycle-risk (CCR) score. METHODS Paraffin sections from 761 men with clinically localized prostate cancer diagnosed by needle biopsy and managed conservatively in the United Kingdom, mostly between 2000 and 2003. The primary end point was prostate cancer death. Clinical variables consisted of centrally reviewed Gleason score, baseline PSA level, age, clinical stage, and extent of disease; these were combined into a single predefined risk assessment (CAPRA) score. Full data were available for 585 men who formed a fully independent validation cohort. RESULTS In univariate analysis, the CCP score hazard ratio was 2.08 (95% CI (1.76, 2.46), P<10(-13)) for one unit change of the score. In multivariate analysis including CAPRA, the CCP score hazard ratio was 1.76 (95% CI (1.44, 2.14), P<10(-6)). The predefined CCR score was highly predictive, hazard ratio 2.17 (95% CI (1.83, 2.57), χ(2)=89.0, P<10(-20)) and captured virtually all available prognostic information. CONCLUSIONS The CCP score provides significant pretreatment prognostic information that cannot be provided by clinical variables and is useful for determining which patients can be safely managed conservatively, avoiding radical treatment.
Collapse
Affiliation(s)
- J Cuzick
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - S Stone
- Myriad Genetics, Inc., Salt Lake City, UT, USA
| | - G Fisher
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - Z H Yang
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - B V North
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
| | - D M Berney
- Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - L Beltran
- Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - D Greenberg
- National Cancer Registration Service (Eastern Office), Public Health England, Cambridge, UK
| | - H Møller
- Cancer Epidemiology and Population Health, King's College London, London, UK
| | - J E Reid
- Myriad Genetics, Inc., Salt Lake City, UT, USA
| | - A Gutin
- Myriad Genetics, Inc., Salt Lake City, UT, USA
| | | | - M Brawer
- Myriad Genetics, Inc., Salt Lake City, UT, USA
| | - P Scardino
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
30
|
Cuzick JM, Stone S, Fisher G, North B, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT. Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e16040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jack M. Cuzick
- Wolfson Institute of Preventive Medicine, London, United Kingdom
| | | | - Gabrielle Fisher
- Wolfson Institute of Preventive Medicine, London, United Kingdom
| | - Bernard North
- Centre for Cancer Prevention, Queen Mary University of London, London, United Kingdom
| | - Daniel M. Berney
- Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom
| | | | - David Greenberg
- Eastern Cancer Registration and Information Centre, National Health Service, Cambridge, United Kingdom
| | - Henrik Møller
- King's College London, Cancer Epidemiology and Population Health, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
31
|
Cuzick J, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D, Møller H, Reid J, Gutin A, Lanchbury J, Brawer M, Scardino P. MP1-10 VALIDATION OF AN ACTIVE SURVEILLANCE THRESHOLD FOR THE CCP SCORE IN CONSERVATIVELY MANAGED MEN WITH LOCALIZED PROSTATE CANCER. J Urol 2015. [DOI: 10.1016/j.juro.2015.02.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Stone S, Cuzick JM, Fisher G, Yang ZH, North B, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT. Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.7_suppl.54] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
54 Background: Active surveillance (AS) is an increasingly popular treatment modality for men with localized prostate cancer. However, better risk stratification is needed to appropriately select men for AS. The cell cycle progression (CCP) score has proven to be a robust predictor of prostate cancer outcomes in various clinical settings, including conservatively managed cohorts. Here, we present a validation of an AS threshold for a predefined score that combines CCP with CAPRA (combined clinical CCP risk (CCR) score) for predicting prostate cancer mortality (PCM) in conservatively managed patients. Methods: We determined the CCR score distribution in 505 men who were tested in our clinical laboratory and, based on their clinical characteristics, might typically be considered for AS. Specifically, the training cohort consisted of men who had Gleason score ≤ 3+4; PSA < 10 ng/ml; < 25% cores positive; and clinical stage ≤ T2a. A threshold CCR score of 0.80 was selected such that 90% of the men in the training cohort had scores below the threshold. The performance characteristics of the threshold were then evaluated in two independent cohorts of conservatively managed men (TAPG1 [N= 180] and TAPG2 [N=585]). Survival data were censored at 10 years. Results: The primary pre−planned analysis called for evaluating the CCR threshold on TAPG2. There were 60 men (of 585) below the threshold in the validation cohort and the threshold validated, dichotomizing the cohort into high and low risk groups (log rank P−value = 0.0008). There were no deaths in patients below the threshold and the Cox proportional hazard estimate of 10−year PCM associated with the CCR threshold was 3.3%. The 10−year risk of PCM associated with the threshold in the combined cohort (TAPG1 and TAPG2) was 3.2% and there were no observed prostate cancer deaths in patients below the threshold. Conclusions: For patients considering deferred treatment, the CCR score provides significant prognostic information at disease diagnosis. The threshold presented here was derived from the ‘typical’ risk of PSM for AS patients and can be used to guide patient selection for AS based on an integrated view of risk assessment.
Collapse
Affiliation(s)
- Steven Stone
- Myriad Genetic Laboratories, Inc., Salt Lake City, UT
| | - Jack M. Cuzick
- Wolfson Institute of Preventive Medicine, London, United Kingdom
| | - Gabrielle Fisher
- Wolfson Institute of Preventive Medicine, London, United Kingdom
| | - Zi Hua Yang
- Wolfson Institute of Preventive Medicine, London, United Kingdom
| | - Bernard North
- Centre for Cancer Prevention, Queen Mary University of London, London, United Kingdom
| | - Daniel M. Berney
- Department of Histopathology, St. Bartholomew's Hospital, London, United Kingdom
| | | | - David Greenberg
- Eastern Cancer Registration and Information Centre, National Health Service, Cambridge, United Kingdom
| | - Henrik Møller
- King's College London, Thames Cancer Registry, London, United Kingdom
| | - Julia E. Reid
- Myriad Genetic Laboratories, Inc., Salt Lake City, UT
| | | | | | | | | |
Collapse
|
33
|
Carter C, Reid T, Fisher G, Cho-Phan C, Kunz P, Kaiser H, Oronsky B, Fanger G, Caroen S, Parker C, Scicinski J. Early Results: “ROCKET” a phase II Study of RRx-001, a novel triple epigenetic inhibitor, Resensitization to Irinotecan in Colorectal Cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv081.8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Vasiljević N, Ahmad AS, Thorat MA, Fisher G, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT. DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer 2014; 14:655. [PMID: 25193387 PMCID: PMC4162944 DOI: 10.1186/1471-2407-14-655] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2014] [Accepted: 08/30/2014] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Prostate cancer has a variable clinical behaviour with frequently unpredictable outcome. DNA methylation plays an important role in determining the biology of cancer but prognostic information is scanty. We assessed the potential of gene-specific DNA methylation changes to predict death from prostate cancer in a cohort of untreated men in the UK. METHODS This was a population-based study in which cases were identified from six cancer registries in Great Britain. DNA was extracted from formalin-fixed paraffin wax-embedded transurethral prostate resection tissues collected during 1990-96 from men with clinically-localised cancer who chose not to be treated for at least 6 months following diagnosis. The primary end point was death from prostate cancer. Outcomes were determined through medical records and cancer registry records. Pyrosequencing was used to quantify methylation in 13 candidate genes with established or suggested roles in cancer. Univariate and multivariate Cox models were used to identify possible predictors for prostate cancer-related death. RESULTS Of 367 men, 99 died from prostate cancer during a median of 9.5 years follow-up (max = 20). Univariately, 12 genes were significantly associated with prostate cancer mortality, hazard ratios ranged between 1.09 and 1.28 per decile increase in methylation. Stepwise Cox regression modelling suggested that the methylation of genes HSPB1, CCND2 and DPYS contributed objective prognostic information to Gleason score and PSA with respect to cancer-related death during follow-up (p = 0.006). CONCLUSION Methylation of 13 genes was analysed in 367 men with localised prostate cancer who were conservatively treated and stratified with respect to death from prostate cancer and those who survived or died of other causes. Of the 13 genes analysed, differential methylation of HSPB1, CCND2 and DPYS provided independent prognostic information. Assessment of gene-methylation may provide independent objective information that can be used to segregate prostate cancers at diagnosis into predicted behavioural groups.
Collapse
Affiliation(s)
- Nataša Vasiljević
- />Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, EC1M 6BQ UK
| | - Amar S Ahmad
- />Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, EC1M 6BQ UK
| | - Mangesh A Thorat
- />Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, EC1M 6BQ UK
| | - Gabrielle Fisher
- />Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, EC1M 6BQ UK
| | - Daniel M Berney
- />Molecular Oncology Centre, Barts Cancer Institute, Queen Mary University of London, London, EC1M 6BQ UK
| | - Henrik Møller
- />King’s College London, Cancer Epidemiology and Population Health, London, SE1 9RT UK
| | - Christopher S Foster
- />HCA International Pathology Laboratories, 2-22 Capper Street, London, WC1E 6JA UK
| | - Jack Cuzick
- />Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, EC1M 6BQ UK
| | - Attila T Lorincz
- />Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, London, EC1M 6BQ UK
| |
Collapse
|
35
|
Cuzick J, Stone S, Fisher G, North B, Berney D, Beltran L, Greenberg D, Moller H, Reid J, Gutin A, Lanchbury J, Brawer M, Scardino P. Combined Analysis of an Rna Cell Cycle Progression (Ccp) Score for Predicting Prostate Cancer Death in Two Conservatively Managed Needle Biopsy Cohorts. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Cuzick JM, Stone S, Fisher G, Yang ZH, North B, Berney D, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer MK, Scardino PT. Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.5059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jack M. Cuzick
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom
| | | | - Gabrielle Fisher
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom
| | - Zi Hua Yang
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom
| | - Bernard North
- Centre for Cancer Prevention, Queen Mary University of London, London, United Kingdom
| | | | | | - David Greenberg
- Eastern Cancer Registration and Information Centre, National Health Service, Cambridge, United Kingdom
| | - Henrik Møller
- King's College London, Thames Cancer Registry, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
37
|
Cuzick J, Stone S, Yang ZH, Reid J, Fisher G, Berney D, Beltran L, Moller H, Greenberg D, Brawer M, Gutin A, Lanchbury J, Scardino P. MP79-17 VALIDATION OF A 46-GENE CELL CYCLE PROGRESSION (CCP) RNA SIGNATURE FOR PREDICTING PROSTATE CANCER DEATH IN A CONSERVATIVELY MANAGED WATCHFUL WAITING NEEDLE BIOPSY COHORT. J Urol 2014. [DOI: 10.1016/j.juro.2014.02.2520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
38
|
Merson S, Yang ZH, Brewer D, Olmos D, Eichholz A, McCarthy F, Fisher G, Kovacs G, Berney DM, Foster CS, Møller H, Scardino P, Cuzick J, Cooper CS, Clark JP. Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer 2014; 110:1655-62. [PMID: 24481405 PMCID: PMC3960602 DOI: 10.1038/bjc.2014.13] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Revised: 12/18/2013] [Accepted: 12/19/2013] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND Androgen receptor (AR)-gene amplification, found in 20-30% of castration-resistant prostate cancer (CRPCa) is proposed to develop as a consequence of hormone-deprivation therapy and be a prime cause of treatment failure. Here we investigate AR-gene amplification in cancers before hormone deprivation therapy. METHODS A tissue microarray (TMA) series of 596 hormone-naive prostate cancers (HNPCas) was screened for chromosome X and AR-gene locus-specific copy number alterations using four-colour fluorescence in situ hybridisation. RESULTS Both high level gain in chromosome X (≥4 fold; n=4, 0.7%) and locus-specific amplification of the AR-gene (n=6, 1%) were detected at low frequencies in HNPCa TMAs. Fluorescence in situ hybridisation mapping whole sections taken from the original HNPCa specimen blocks demonstrated that AR-gene amplifications exist in small foci of cells (≤ 600 nm, ≤1% of tumour volume). Patients with AR gene-locus-specific copy number gains had poorer prostate cancer-specific survival. CONCLUSION Small clonal foci of cancer containing high level gain of the androgen receptor (AR)-gene develop before hormone deprivation therapy. Their small size makes detection by TMA inefficient and suggests a higher prevalence than that reported herein. It is hypothesised that a large proportion of AR-amplified CRPCa could pre-date hormone deprivation therapy and that these patients would potentially benefit from early total androgen ablation.
Collapse
Affiliation(s)
- S Merson
- Molecular Carcinogenesis, Institute of Cancer Research, Male Urological Cancer Research Centre, Surrey, UK
| | - Z H Yang
- The Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, St Bartholomew's Medical School, Queen Mary, University of London, London, UK
| | - D Brewer
- 1] Molecular Carcinogenesis, Institute of Cancer Research, Male Urological Cancer Research Centre, Surrey, UK [2] Department of Cancer Genetics, University of East Anglia, Norwich, UK
| | - D Olmos
- Prostate Cancer Research, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 28029 Madrid, Spain
| | - A Eichholz
- Molecular Carcinogenesis, Institute of Cancer Research, Male Urological Cancer Research Centre, Surrey, UK
| | - F McCarthy
- Molecular Carcinogenesis, Institute of Cancer Research, Male Urological Cancer Research Centre, Surrey, UK
| | - G Fisher
- The Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, St Bartholomew's Medical School, Queen Mary, University of London, London, UK
| | - G Kovacs
- Laboratory of Molecular Oncology, Medical Faculty, Ruprecht-Karls-Universitat, Heidelberg, Germany
| | - D M Berney
- Department of Molecular Oncology, Barts Cancer Institute, Charterhouse Square, London, UK
| | - C S Foster
- Molecular Pathology Laboratory, Liverpool University, Liverpool, UK and HCA Laboratories, London, UK
| | - H Møller
- 1] The Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, St Bartholomew's Medical School, Queen Mary, University of London, London, UK [2] King's College London, Cancer Epidemiology and Population Health, London, UK
| | - P Scardino
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - J Cuzick
- The Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, St Bartholomew's Medical School, Queen Mary, University of London, London, UK
| | - C S Cooper
- Department of Cancer Genetics, University of East Anglia, Norwich, UK
| | - J P Clark
- Department of Cancer Genetics, University of East Anglia, Norwich, UK
| | | |
Collapse
|
39
|
Vasiljević N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT. DNA methylation of PITX2 predicts poor survival in men with prostate cancer. Biomark Med 2014; 8:1143-50. [PMID: 25402584 DOI: 10.2217/bmm.14.41] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AIM We investigated if methylation of candidate genes can be useful for predicting prostate cancer (PCa) specific death. PATIENTS & METHODS Methylation of PITX2, WNT5a, SPARC, EPB41L3 and TPM4 was investigated in a 1:2 case-control cohort comprising 45 men with cancer of Gleason score ≤ 7 who died (cases), and 90 men who were alive or died of other causes with survival time longer than the cases (controls). A univariate conditional logistic regression model was fitted by maximizing the likelihood of DNA methylation of each gene versus the primary end point. RESULTS A 10% increase in methylation of PITX2 was associated with PCa related death with OR 1.56 (95% CI: 1.17-2.08; p = 0.005). CONCLUSION Our study strengthens prior findings that PITX2 methylation is useful as a biomarker of poor outcome of PCa and in addition we also suggest that it may be particularly useful in men with low Gleason score.
Collapse
Affiliation(s)
- Nataša Vasiljević
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts & London School of Medicine, Queen Mary University of London, London, EC1M 6BQ, UK
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Molugu C, Fisher G, Hirons B, Hughes D, Raftery S. P151 V-DimERS Study - Value of D-Dimers in Estimating Risk of Significant Pulmonary Embolism and Deep Vein Thrombosis: Abstract P151 Table 1. Thorax 2013. [DOI: 10.1136/thoraxjnl-2013-204457.301] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
41
|
Spooner B, Fisher G. Peri-operative fitness: a question of stamina? Anaesthesia 2013; 68:1280-1. [PMID: 24219263 DOI: 10.1111/anae.12473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Krishnan M, Beck S, Cowen O, Hughes M, Havelock W, Eeles E, Hubbard R, Johansen A, Michael A, Teo PJ, Fisher G, Duggan E, Donoghue O, Savva G, Cronin H, Kenny R, Finucane C, Bhutta T, Musarrat K, Lakhani D, Musarrat K, Bhutta T, Kumar M, Bridge D, Patel A, Lakhani D, Marchetti R, Bullman N, Srikusalankul W, Varendran R, Anderson-Ranberg K, Ryg J, Vestergaard S, Eriksen ML, Masud T. Falls, fracture and trauma. Age Ageing 2013. [DOI: 10.1093/ageing/aft101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Robinson R, Nelson C, Kisling K, Fisher G, Kirsner S. SU-E-T-334: APBI Contralateral Breast Dose. Med Phys 2013. [DOI: 10.1118/1.4814768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
44
|
Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013; 108:2582-9. [PMID: 23695019 PMCID: PMC3694239 DOI: 10.1038/bjc.2013.248] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Background: The natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of phosphatase and tensin homologue (PTEN) loss in a cohort of 675 men with conservatively managed prostate cancer diagnosed by transurethral resection of the prostate. Methods: The PTEN status was assayed by immunohistochemistry (PTEN IHC) and fluorescent in situ hybridisation (PTEN FISH). The primary end point was death from prostate cancer. Results: The PTEN IHC loss was observed in 18% cases. This was significantly associated with prostate cancer death in univariate analysis (hazard ratio (HR)=3.51; 95% CI 2.60–4.73; P=3.1 × 10−14). It was highly predictive of prostate cancer death in the 50% of patients with a low risk score based on Gleason score, PSA, Ki-67 and extent of disease (HR=7.4; 95% CI 2.2–24.6; P=0.012) ), but had no prognostic value in the higher risk patients. The PTEN FISH loss was only weakly associated with PTEN IHC loss (κ=0.5). Both PTEN FISH loss and amplification were univariately predictive of death from prostate cancer, but this was not maintained in the multivariate analyses. Conclusion: In low-risk patients, PTEN IHC loss adds prognostic value to Gleason score, PSA, Ki-67 and extent of disease.
Collapse
Affiliation(s)
- J Cuzick
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, EC1M 6BQ, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Brawer MK, Cuzick JM, Cooperberg MR, Swanson GP, Freedland SJ, Reid JE, Fisher G, Lanchbury JS, Gutin A, Stone S, Carroll P. Prolaris: A novel genetic test for prostate cancer prognosis. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.5005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5005 Background: The natural history of prostate cancer is highly variable and difficult to predict. Improved tools are needed to match treatment more appropriately to a patient’s risk of progression. Therefore, we developed an expression signature composed of genes involved in cell cycle progression (Prolaris) and tested its utility in prostate cancer. Methods: We developed an expression signature composed of 31 cell cycle progression and 15 housekeeper genes. An expression score (Prolaris score) was derived as the mean of all cell cycle progression genes. The signature was tested at disease diagnosis in two conservatively managed cohorts from the UK (N=337 and 349), after radical prostatectomy in two cohorts from the U.S. (N=366 Scott & White Hospital, TX and 413 USCF, CA), and after external beam radiation therapy (N=141) in a cohort from Durham VA Medical Center. All studies were retrospective. Results: The cell cycle progression signature was a highly significant predictor of outcome in all five studies. In conservatively managed patients, the Prolaris score was the dominant variable for predicting death from prostate cancer in univariate analysis (p = 6.1 x 10-22 after diagnosis by TURP, and p = 8.6 x 10-10 after diagnosis by needle biopsy). In both studies, the Prolaris score remained highly significant in multivariate analysis making it a stronger predictor of disease-specific mortality than other prognostic variables. After prostatectomy, Prolaris predicted biochemical recurrence (BCR) in univariate analysis (S&W p = 5.6 x 10-9; UCSF p= 2.23 x 10-6) and provided additional prognostic information in multivariate analysis (S&W p = 3.3 x10-6; UCSF 9.5 x10-5). After radiation therapy, Prolaris predicted BCR (Phoenix) in univariate (p=0.0017) and multivariate analysis (p=0.034). In all five studies the HR per unit change in the Prolaris score was remarkably similar, ranging from 1.89 to 2.92, indicating that the effect size for the Prolaris score is robust to clinical setting and patient composition. Conclusions: The Prolaris test predicts prostate cancer outcome in multiple patient cohorts and diverse clinical settings. In all cases, it provides information beyond clinicopathologic variables to help differentiate aggressive from indolent disease.
Collapse
Affiliation(s)
| | - Jack M. Cuzick
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom
| | | | - Gregory P. Swanson
- University of Texas Health Science Center at San Antonio, San Antonio, TX
| | | | - Julia E. Reid
- Myriad Genetics and Laboratories, Inc., Salt Lake City, UT
| | - Gabrielle Fisher
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, London, United Kingdom
| | | | | | - Steven Stone
- Myriad Genetics and Laboratories, Inc., Salt Lake City, UT
| | - Peter Carroll
- University of California, San Francisco, San Francisco, CA
| | | |
Collapse
|
46
|
Ahmad I, Singh LB, Yang ZH, Kalna G, Fleming J, Fisher G, Cooper C, Cuzick J, Berney DM, Møller H, Scardino P, Leung HY. Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br J Cancer 2013; 108:149-54. [PMID: 23321517 PMCID: PMC3553517 DOI: 10.1038/bjc.2012.510] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)–extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (CaP). The mechanism for ERK5 activation in CaP remains to be fully elucidated. Studies have recently implicated the role of microRNA (miRNA) mir143 expression in the regulation of ERK5 expression. Methods: We utilised a tissue microarray (TMA) of 530 CaP cores from 168 individual patients and stained for both mir143 and ERK5. These TMAs were scored by a combination of observer and automated methods. Results: We observed a strong inverse relation between ERK5 and mir143, which manifested itself most strongly in the subgroup of 417 cores with non-zero mir143 and ERK5 immunoreactivity, or with only one of mir143 or ERK5 being zero (cc=0.2558 and P<0.0001). Mir143 neither correlate with Gleason scores or prostate-specific antigen levels, nor was it a predictor of disease-specific survival on univariate analysis. Conclusion: Although the mechanism for ERK5 activation in CaP remains to be fully elucidated, we have further validated the potential role of mir143 in regulating ERK5 levels in the clinical context. In addition, we demonstrate that the automated counting method for nuclear ERK5 is a clinically useful alterative to observer counting method in patient stratification in the context of ERK5 targeting therapy.
Collapse
Affiliation(s)
- I Ahmad
- Beatson Institute for Cancer Research, Bearsden, Glasgow G61 1BD, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Khoshkhahesh F, Siahkuhain M, Fisher G, Nakhostin-Roohi B. Influence of a low-dose cox-2 inhibitor drug on exercise-induced inflammation, muscle damage and lipid peroxidation. Biol Sport 2013; 30:61-5. [PMID: 24744468 PMCID: PMC3944556 DOI: 10.5604/20831862.1029824] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/09/2012] [Indexed: 11/22/2022] Open
Abstract
The purpose of this study was to examine the effect of acute low-dose celecoxib administration on exercise-induced inflammation, muscle damage and lipid peroxidation. Twenty healthy untrained males (age: 25.5±4.5 yrs, weight: 72.7±7.9 kg, height: 177.3±7.2 cm) were randomly assigned to treatment (T) or placebo (P) groups. Blood samples were obtained before, immediately after, 3 h after and 24 h after exercise. Subjects ran for 30 min at 75% V.O2 max on a treadmill. Participants consumed 100 mg celecoxib or a placebo immediately after and 12 h after the immediately post-exercise blood sample. Total leukocytes, neutrophils, creatine kinase (CK), C-reactive protein (CRP) and malondialdehyde (MDA) were assessed at each time point. Significant increases in total leukocytes and neutrophils were observed 3 h after exercise in both groups (P < 0.05). CK and CRP levels were significantly increased immediately, 3 h and 24 h after exercise in both groups (P < 0.05). A significant increase in MDA was observed immediately after exercise in both groups (P < 0.05); however, no significant group differences were observed for MDA or CK. These findings suggest that inhibition of cyclo-oxygenase activity with low-dose celecoxib does not affect exercise-induced inflammation, muscle damage, or lipid peroxidation.
Collapse
Affiliation(s)
- F Khoshkhahesh
- Department of Exercise Physiology, Ardabil Branch, Islamic Azad University, Iran
| | - M Siahkuhain
- Department of Exercise Physiology, University of Mohaghegh-Ardabili, Iran
| | - G Fisher
- Department of Nutrition Sciences University of Alabama at Birmingham, Birmingham, AL, USA
| | - B Nakhostin-Roohi
- Department of Exercise Physiology, Ardabil Branch, Islamic Azad University, Iran
| |
Collapse
|
48
|
Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, Berney DM. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer 2013; 108:271-7. [PMID: 23329234 PMCID: PMC3566811 DOI: 10.1038/bjc.2012.598] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background: Standard clinical parameters cannot accurately differentiate indolent from aggressive prostate cancer. Our previous work showed that immunohistochemical (IHC) Ki-67 improved prediction of prostate cancer death in a cohort of conservatively treated clinically localised prostate cancers diagnosed by transurethral resection of the prostate (TURP). Here, we present results in a more clinically relevant needle biopsy cohort. Methods: Biopsy specimens were microarrayed. The percentage of Ki-67 positively stained malignant cells per core was measured and the maximum score per individual used in analysis of time to death from prostate cancer using a Cox proportional hazards model. Results: In univariate analysis (n=293), the hazard ratio (HR) (95% confidence intervals) for dichotomous Ki-67 (⩽10%, >10%) was 3.42 (1.76, 6.62) χ2 (1 df)=9.8, P=0.002. In multivariate analysis, Ki-67 added significant predictive information to that provided by Gleason score and prostate-specific antigen (HR=2.78 (1.42, 5.46), χ2 (1 df)=7.0, P=0.008). Conclusion: The IHC Ki-67 scoring on prostate needle biopsies is practicable and yielded significant prognostic information. It was less informative than in the previous TURP cohort where tumour samples were larger and more comprehensive, but in more contemporary cohorts with larger numbers of biopsies per patient, Ki-67 may prove a more powerful biomarker.
Collapse
Affiliation(s)
- G Fisher
- Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Staley KG, Fisher G, Brightling CE, Bradding P, Parker D, Gaillard EA. S79 Sputum Inflammatory Cell Profile in Children with Acute Asthma and Following Recovery: Abstract S79 Table 1. Thorax 2012. [DOI: 10.1136/thoraxjnl-2012-202678.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
50
|
Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Møller H, Cooper CS, Cuzick J, Berney DM. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch 2012; 461:103-7. [PMID: 22767265 DOI: 10.1007/s00428-012-1259-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2012] [Revised: 05/10/2012] [Accepted: 05/28/2012] [Indexed: 11/26/2022]
Abstract
In vitro studies have implicated neuroendocrine differentiation in the development of hormone resistant prostate cancer following administration of androgen blockers. Studies on clinical material are equivocal. We wished to understand the significance of neuroendocrine differentiation in our large and well-characterised cohort of clinically localised prostate cancer, treated conservatively. Immunohistochemical expression of chromogranin-A was assessed semi-quantitatively on tissue samples of 806 patients in a tissue microarray approach. The correlation of expression with 10-year prostate cancer survival was examined. Multivariate analysis including contemporary Gleason score was performed and sub-group analysis of early hormone treated patients was also undertaken. Chromogranin-A expression correlated with high Gleason score (χ(2) = 28.35, p < 0.001) and early prostate cancer death (HR = 1.61, 95 %CI = 1.15-2.27, p < 0.001). In univariate analysis, NE differentiation correlated significantly with outcome (HR = 1.61, 95 % CI 1.15-2.27, p < 0.001) However in multivariate analysis including Gleason score, chromogranin-A expression was not an independent predictor of survival (HR = 0.97, 95 %CI = 0.89-1.37, p = 0.87). Although chromogranin-A expression was higher in patients with early hormone therapy (χ(2) = 7.25, p = 0.007), there was no association with prostate cancer survival in this sub-group (p = 0.083). Determination of neuroendocrine differentiation does not appear to have any bearing on the outcome of prostatic carcinoma and does not add to the established prognostic model.
Collapse
Affiliation(s)
- S S Jeetle
- Department of Molecular Oncology, Barts Cancer Institute, Charterhouse Square, London, EC1M 6BQ, UK
| | | | | | | | | | | | | | | |
Collapse
|